Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRX-2 Regimen and Durvalumab in Incurable Head and Neck Squamous Cell Carcinoma
NCT03381183Phase 1Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Aug 2019
- Primary completion
- May 2022
- Modality
- Antibody Conjugates, Cytokines & Interferons, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label trial of citoplurikin and durvalumab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Moffitt Cancer Center. Primary endpoint: Maximum Tolerated Dose at 12 months. Started Aug 2019; status: completed.
02
Drugs
citoplurikindurvalumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03381183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03381183.